Page 440 - شرور شركات الأدوية

‫ﴍور ﴍﻛﺎت اﻷدوﻳﺔ‬

(10) Prayle AP, Hurley MN, Smyth AR (2012) Data from: Compli-
ance with mandatory reporting of clinical trial results on ClinicalTri-
als.gov: cross sectional study. Dryad Digital Repository.doi:10.5061/dryad
.j512f21p

(11) Simmonds MC, Brown JVE, Heirs MK, Higgins JPT, Mannion RJ,
Rodgers MA, et al. Safety and Effectiveness of Recombinant Human Bone
Morphogenetic Protein-2 for Spinal Fusion: A Meta-analysis of Individual-
Participant Data. Ann Intern Med. 2013;158(12):877–889.

(12) Davis C, Abraham J. Is there a cure for corporate crime in the drug
industry? BMJ. 2013;346:f755.

(13) Gale EAM. Post-marketing studies of new insulins: sales or sci-
ence? BMJ. 2012;344:e3974.

(14) Light DW, Lexchin JR. Pharmaceutical research and development:
what do we get for all that money? BMJ. 2012;345:e4348.

(15) Svensson S, Menkes DB, Lexchin J. Surrogate Outcomes in Clinical
Trials: A Cautionary Tale. JAMA Intern Med. 2013;173(8):611-612.

(16) “JAMA, Integrity, Accessibility, and Social vs. Scientific Peer Re-
view”. Emergency Medicine Literature of Note, Feb 26, 2013.

(17) Abbasi, K. Blood on our hands: seeing the evil in inappropriate
comparators. J R Soc Med. 2013 January;106(1): 1.

(18) Inside Health, BBC Radio 4, January 2013.
(19) Duijnhoven RG, Straus SMJM, Raine JM, de Boer A, Hoes
AW, et al. (2013) Number of Patients Studied Prior to Approval of
New Medicines: A Database Analysis. PLoS Med 10(3): e1001407.
doi:10.1371/journal.pmed.1001407.
(20) Ioannidis JPA. How Many Contemporary Medical Practices Are
Worse Than Doing Nothing or Doing Less? Mayo Clinic Proceedings. 2013
Aug;88(8):779–81.

440